Randomised, Double-blind, parallel-group, active-comparator(venlafaxine extended release), fixed-dose study of LuAA21004 in Major Depressive Disorder in Asian countries

Trial Profile

Randomised, Double-blind, parallel-group, active-comparator(venlafaxine extended release), fixed-dose study of LuAA21004 in Major Depressive Disorder in Asian countries

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Vortioxetine (Primary) ; Venlafaxine
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Acronyms SOLUTION
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 24 May 2017 Results assessing the overall performance priority the antidepressants: vortioxetine, agomelatine and venlafaxine XR in patients from two randomised trials (SOLUTION and REVIVE), presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • 01 Oct 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Apr 2013 Planned end date changed from 1 Jul 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top